Company intelligence / Profile preview

Apurano Pharmaceuticals GmbH

Warngau, Bayern (Bavaria), Germanyapurano.de ↗
Ownership
Private
Employees
~9
Development stage
Other
01

Overview

Apurano is conducting Phase III trials for Adezunap in chronic pain and multiple sclerosis. The company is a leader in cannabinoid-based therapies for pain management, with multiple Phase III pain trials underway[6][7].

Therapeutic areas
EndocrinologyNeurology
Modalities
Small molecule drugsHerbal medicineBiological productsNanotechnology formulations
Industry
Biotech
02

Drug pipeline

6 assets

adezunap

3

5 more assets in the full pipeline.

Beyond the preview

Go deeper on Apurano Pharmaceuticals GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Apurano Pharmaceuticals GmbH.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call